Nervgen Pharma (NGEN) Total Current Liabilities (2024 - 2026)

Nervgen Pharma (NGEN) has reported Total Current Liabilities for 3 consecutive years, with $52.7 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Current Liabilities changed N/A year-over-year to $52.7 million in Q2 2026; TTM through Jun 2026 was $52.7 million, a N/A change from a year earlier, with the FY2025 full-year figure at $14.2 million, up 14.62% from the prior year.
• Total Current Liabilities was $52.7 million for Q2 2026 at Nervgen Pharma, up from $11.1 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $52.7 million in Q2 2026 and troughed at $11.1 million in Q1 2026.
• A 3-year average of $22.5 million and a median of $13.1 million in 2024 frame the typical range for Total Current Liabilities.
• The widest YoY moves for Total Current Liabilities: up 16.95% in 2025, down 16.95% in 2025.
• Over 3 years, Total Current Liabilities stood at $12.1 million in 2024, then increased by 16.95% to $14.2 million in 2025, then soared by 272.52% to $52.7 million in 2026.
• The last three Total Current Liabilities figures came in at $52.7 million (Q2 2026), $11.1 million (Q1 2026), and $14.2 million (Q4 2025), per Business Quant data.